InspireMD Analyst Price Targets

Wall Street analyst price targets and consensus rating for InspireMD (NSPR).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$4Upside to Avg. PT+535.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 5, 2026	Piper Sandler	Adam Maeder	PT Cut	Overweight	$4→$3
May 12, 2025	Piper Sandler	Adam Maeder	PT Cut	Overweight	$5→$4
Dec 11, 2024	Lake Street	Frank Takkinen	Initiate	Buy	$5
Sep 17, 2024	Piper Sandler	Adam Maeder	Maintained	Overweight	$5
Nov 2, 2023	Piper Sandler	Adam Maeder	PT Raise	Overweight	$4→$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on InspireMD, Lowers Price Target to $4

Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4.5 to $4.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

Lake Street analyst Frank Takkinen initiates coverage on InspireMD (NASDAQ:NSPR) with a Buy rating and announces Price Target of $5.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and maintains $4.5 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5

Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and raises the price target from $3.5 to $4.5.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023

Benzinga Insights

InspireMD Inc

InspireMD Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

PRO
Piper Sandler Maintains Overweight on InspireMD, Lowers Price Target to $4

PRO
Lake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

PRO
Piper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target

PRO
Piper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5

Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023

People Also Watch

People Also Watch

InspireMD Inc

InspireMD Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

PROPiper Sandler Maintains Overweight on InspireMD, Lowers Price Target to $4

PROLake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

PROPiper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target

PROPiper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5

Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023

People Also Watch

People Also Watch

PRO
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

PRO
Piper Sandler Maintains Overweight on InspireMD, Lowers Price Target to $4

PRO
Lake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

PRO
Piper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target

PRO
Piper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5